France grants early access to Janssen's ibrutinib for CLL & MCL
This article was originally published in Scrip
The French regulator, ANSM, has approved an early access program for Janssen's ibrutinib in the treatment of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL), pending its approval via the EU's centralized procedure.
You may also be interested in...
Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.
There is much talk around the importance of clinical trials in finding new treatments and vaccines for COVID-19 patients, but observational studies in clinical practice also have a vital role to play, including the impact on pregnant women.
Switzerland’s medicines agency has cleared Ferring’s carbetocin for preventing uterine haemorrhage under the Marketing Authorization for Global Health Products (MAGHP) procedure, which is intended to accelerate the approval of new products in low- and middle-income countries.